Results 1 to 10 of about 2,979 (199)
Some of the next articles are maybe not open access.
pharma-kritik, 2019
Ein neues Neuroleptikum, das ungefähr dieselben Wirkungen hat wie Aripiprazol, aber durch eine sehr lange Halbwertszeit auffällt.
openaire +1 more source
Ein neues Neuroleptikum, das ungefähr dieselben Wirkungen hat wie Aripiprazol, aber durch eine sehr lange Halbwertszeit auffällt.
openaire +1 more source
Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
Brexpiprazole, cariprazine hydrochloride, and flibanserin
Journal of the American Pharmacists Association, 2016Brexpiprazole (RexultidOtsuka) is an atypical antipsychotic agent with properties and uses that are most similar to those of aripiprazole (e.g., Abilify). It is indicated for the treatment of patients with schizophrenia, and for adjunctive treatment in patients with major depressive disorder (MDD).
Daniel A, Hussar, Rebecca, Shatynski
openaire +2 more sources
Cariprazine: A Review in Schizophrenia
CNS Drugs, 2017Cariprazine (Vraylar™) is a dopamine D3-preferring D2/D3 receptor partial agonist indicated for the treatment of patients with schizophrenia. This narrative review summarizes pharmacological, efficacy and tolerability data relevant to the use of cariprazine in patients with this disorder.
openaire +2 more sources
Psychopharmacology Bulletin
This case of a 10-year-old girl herein presented is one of the earliest to report safe and effective use of cariprazine, a metabolic-friendly agent, targeting the behavioral facets in ASD. This might open new treatment venues in such complicated clinical scenarios.
Ahmed Naguy +2 more
openaire +1 more source
This case of a 10-year-old girl herein presented is one of the earliest to report safe and effective use of cariprazine, a metabolic-friendly agent, targeting the behavioral facets in ASD. This might open new treatment venues in such complicated clinical scenarios.
Ahmed Naguy +2 more
openaire +1 more source
Cariprazine: First Global Approval
Drugs, 2015Cariprazine (Vraylar) is an oral atypical antipsychotic originated by Gedeon Richter. It is a potent dopamine D3 and D2 receptor partial agonist, which preferentially binds to the D3 receptor. Cariprazine also has partial agonist activity at serotonin 5-HT1A receptors. In September 2015, cariprazine received its first global approval in the USA for the
openaire +2 more sources
Minerva Psichiatrica e Psicologica, 2017
INTRODUCTION: Cariprazine (RGH-188) is a novel antipsychotic drug that exerts partial agonism of dopamine D2/D3 receptors with preferential binding to D3 receptor, antagonism of 5HT2B receptors and partial agonism of 5HT1A. Its interesting pharmacodynamic profile suggests its potential in the treatment of a plethora of psychiatric disorders.
Orsolini, Laura +15 more
openaire +1 more source
INTRODUCTION: Cariprazine (RGH-188) is a novel antipsychotic drug that exerts partial agonism of dopamine D2/D3 receptors with preferential binding to D3 receptor, antagonism of 5HT2B receptors and partial agonism of 5HT1A. Its interesting pharmacodynamic profile suggests its potential in the treatment of a plethora of psychiatric disorders.
Orsolini, Laura +15 more
openaire +1 more source